Explosive OTC stock: BSEM
BioStem is a manufacturer for wound care. Innovation new product and very succesful
Technical:
(+) Nice run from last year (product launch), volume increasing
(+) consolidation area lower volume
(-) wide range consolidation
Fundamental:
(+) New product launch in Q4/2023. Great revenue increase last quarter.
(+) Outlook Q4 > 100 Mio revenue --> except minimum 0,35 EPS next quarter.
(+) Market capitalization below revenue
(- / +) OTC stock, but want goes for nasdaq listing
Due to OTC listing, the stock could be a hidden gem but riskier.
Technical:
(+) Nice run from last year (product launch), volume increasing
(+) consolidation area lower volume
(-) wide range consolidation
Fundamental:
(+) New product launch in Q4/2023. Great revenue increase last quarter.
(+) Outlook Q4 > 100 Mio revenue --> except minimum 0,35 EPS next quarter.
(+) Market capitalization below revenue
(- / +) OTC stock, but want goes for nasdaq listing
Due to OTC listing, the stock could be a hidden gem but riskier.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.